Hepatorenal Syndrome

Categories: Gastrointestinal diseases, Liver diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Hepatorenal Syndrome

MalaCards integrated aliases for Hepatorenal Syndrome:

Name: Hepatorenal Syndrome 12 74 52 54 43 15 71 32
Hepato-Renal Syndrome 52


External Ids:

Disease Ontology 12 DOID:11823
ICD9CM 34 572.4
MeSH 43 D006530
NCIt 49 C113400
SNOMED-CT 67 51292008
ICD10 32 K76.7
UMLS 71 C0019212

Summaries for Hepatorenal Syndrome

NIH Rare Diseases : 52 Hepatorenal syndrome is a form of impaired kidney function that occurs in individuals with advanced chronic liver disease. As many as 40% of individuals with cirrhosis and ascites will develop hepatorenal syndrome. Symptoms may include fatigue, abdominal pain, and a general feeling of ill health (malaise ). There are two distinct types of hepatorenal syndrome. Type I progresses quickly (within days), leading to kidney failure . Individuals with type I typically have dramatically reduced urine output, edema , and jaundice , and often suffer from hepatic encephalopathy . Type II progresses more slowly, over weeks or months, and the symptoms are less severe. The cause of hepatorenal syndrome is unknown. A contributing factor seems to be a narrowing of the blood vessels that connect into the kidneys. This causes a decrease in blood flow to the kidneys, impairing their function. In some cases, triggers or precipitating factors (infections, blood loss from the gastrointestinal tract, low blood pressure) are involved. Treatment is aimed at helping the liver work better and maintaining kidney function. In many cases, a liver transplant is needed. In some cases, individuals also need a kidney transplant .

MalaCards based summary : Hepatorenal Syndrome, also known as hepato-renal syndrome, is related to peritonitis and acute liver failure. An important gene associated with Hepatorenal Syndrome is ALB (Albumin), and among its related pathways/superpathways are Oxytocin signaling pathway and FOXA2 and FOXA3 transcription factor networks. The drugs Clavulanate and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and bone, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 An acute kidney failure that is characterized by severe renal vasoconstriction.

Wikipedia : 74 Hepatorenal syndrome (often abbreviated HRS) is a life-threatening medical condition that consists of... more...

Related Diseases for Hepatorenal Syndrome

Diseases related to Hepatorenal Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 378)
# Related Disease Score Top Affiliating Genes
1 peritonitis 31.1 IL18 F2 AQP1 ALB
2 acute liver failure 30.9 GPT F2 ALB
3 portal hypertension 30.8 GPT F2 EDN1 ALB ACE
4 alcoholic hepatitis 30.8 IL18 GPT F2 ALB
5 hepatic coma 30.5 GPT F2 ALB AFP
6 uremia 30.4 REN ALB ACE
7 cholecystitis 30.3 GPT F2 ALB
8 end stage renal disease 30.3 REN CST3 ALB ACE
9 leptospirosis 30.2 LCN2 IL18 F2 AQP1
10 iga glomerulonephritis 30.2 REN ALB ACE
11 visceral leishmaniasis 30.1 IL18 CST3 ALB
12 obstructive jaundice 30.1 REN GPT F2 EDN1 ALB
13 cholangitis 30.1 GPT F2 ALB
14 infantile liver failure syndrome 1 30.1 GPT F2 ALB
15 compartment syndrome 30.0 LCN2 GPT F2 ALB
16 esophageal varix 30.0 GPT F2 ALB AFP
17 bilirubin metabolic disorder 30.0 GPT F2 ALB AFP
18 alcoholic liver cirrhosis 30.0 GPT F2 ALB AFP
19 hepatitis e 30.0 GPT F2 ALB
20 pulmonary edema 30.0 REN NPPA F2 EDN1 ACE
21 deficiency anemia 30.0 NPPA LCN2 ALB ACE
22 biliary atresia 29.9 GPT F2 ALB
23 portal vein thrombosis 29.9 REN F2 AFP
24 sclerosing cholangitis 29.9 GPT F2 ALB
25 intestinal obstruction 29.8 GPT EDN3 ALB
26 eclampsia 29.8 REN F2 EDN1 ALB ACE
27 peliosis hepatis 29.7 GPT AFP
28 metabolic acidosis 29.7 GPT F2 AQP2 ALB
29 congestive heart failure 29.7 REN NPPA EDN1 AQP2 ALB ACE
30 hepatic encephalopathy 29.7 IL18 GPT F2 ARNTL2 ALB AFP
31 autoimmune hepatitis 29.7 GPT F2 ALB
32 viral hepatitis 29.7 GPT F2 ALB AFP
33 biliary tract disease 29.7 GPT F2 ALB AFP
34 interstitial nephritis 29.6 REN HAVCR1 ALB ACE
35 liver cirrhosis 29.5 REN NPPA GPT F2 EDN1 AVP
36 pulmonary hypertension 29.5 REN NPPA F2 EDN1 ALB ACE
37 membranous nephropathy 29.5 LCN2 HAVCR1 ALB ACE
38 cholangitis, primary sclerosing 29.4 GPT F2 ALB AFP
39 pyelonephritis 29.4 LCN2 GPT AQP2 ALB ACE
40 thrombocytopenia 29.3 IL18 GPT F2 EDN1 ALB
41 hepatitis a 29.2 HAVCR1 GPT F2 ALB AFP
42 kidney disease 28.9 REN NPPA LCN2 IL18 EDN1 CST3
43 acute kidney tubular necrosis 28.6 REN NPPA LCN2 IL18 HAVCR1 CST3
44 anuria 28.5 REN LCN2 HAVCR1 GPT F2 CST3
45 acute kidney failure 28.4 REN NPPA LCN2 IL18 HAVCR1 GPT
46 chronic kidney disease 28.3 REN NPPA LCN2 HAVCR1 EDN1 CST3
47 pre-eclampsia 27.9 REN NPPA IL18 GPT F2 EDN1
48 peroxisome biogenesis disorder 1a 11.8
49 arima syndrome 11.8
50 liver disease 10.6

Comorbidity relations with Hepatorenal Syndrome via Phenotypic Disease Network (PDN):

Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alcoholic Liver Cirrhosis
Deficiency Anemia Heart Disease
Hepatic Encephalopathy Portal Hypertension

Graphical network of the top 20 diseases related to Hepatorenal Syndrome:

Diseases related to Hepatorenal Syndrome

Symptoms & Phenotypes for Hepatorenal Syndrome

MGI Mouse Phenotypes related to Hepatorenal Syndrome:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.06 ACE ALB AQP1 AVPR1A CST3 EDN1
2 hematopoietic system MP:0005397 10 ACE AQP1 AQP2 AVP AVPR1A CABIN1
3 homeostasis/metabolism MP:0005376 10 ACE AFP ALB AQP1 AQP2 AVP
4 mortality/aging MP:0010768 9.8 ACE AFP ALB AQP1 AQP2 AVP
5 renal/urinary system MP:0005367 9.28 ACE ALB AQP1 AQP2 AVP EDN1

Drugs & Therapeutics for Hepatorenal Syndrome

Drugs for Hepatorenal Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 176)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Cefotaxime Approved Phase 4 63527-52-6 5742673 456256
Vancomycin Approved Phase 4 1404-90-6 14969 441141
Cefoxitin Approved Phase 4 35607-66-0 441199
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
Azithromycin Approved Phase 4 83905-01-5 447043 55185
Tranexamic Acid Approved Phase 4 1197-18-8 5526
Norfloxacin Approved Phase 4 70458-96-7 4539
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
Atorvastatin Approved Phase 4 134523-00-5 60823
Norepinephrine Approved Phase 4 51-41-2 439260
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
Valine Approved, Nutraceutical Phase 4 72-18-4 6287
Adefovir Investigational Phase 4 106941-25-7
20 Amoxicillin-Potassium Clavulanate Combination Phase 4
21 beta-Lactamase Inhibitors Phase 4
22 Coagulants Phase 4
23 Reverse Transcriptase Inhibitors Phase 4
24 Antifibrinolytic Agents Phase 4
25 Anti-Infective Agents Phase 4
26 Cytochrome P-450 Enzyme Inhibitors Phase 4
27 Gastrointestinal Agents Phase 4
28 Pharmaceutical Solutions Phase 4
29 Sodium Potassium Chloride Symporter Inhibitors Phase 4
30 Liver Extracts Phase 4
31 Hypolipidemic Agents Phase 4
32 Lipid Regulating Agents Phase 4
33 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
34 Anticholesteremic Agents Phase 4
35 Antimetabolites Phase 4
36 Adrenergic alpha-Agonists Phase 4
37 Adrenergic Agents Phase 4
38 Vasoconstrictor Agents Phase 4
39 Adrenergic Agonists Phase 4
40 Sympathomimetics Phase 4
41 Neurotransmitter Agents Phase 4
42 Angiotensinogen Phase 4
43 Giapreza Phase 4
44 Serine Proteinase Inhibitors Phase 4
protease inhibitors Phase 4
46 HIV Protease Inhibitors Phase 4
47 Anti-Bacterial Agents Phase 4
48 Antibiotics, Antitubercular Phase 4
49 Anticoagulants Phase 4
50 Dextrans Phase 4

Interventional clinical trials:

(show top 50) (show all 112)
# Name Status NCT ID Phase Drugs
1 The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure Unknown status NCT02489864 Phase 4 Terlipressin
2 Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response Unknown status NCT01530711 Phase 4 Terlipressin and albumin
3 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
4 Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
5 Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1) Unknown status NCT03023189 Phase 4 Tranexamic acid;Placebo
6 Randomized Double-Blid Placebo Controlled Trial Assessing Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis In Advanced Cirrhosis Completed NCT00359853 Phase 4 Oral norfloxacin
7 Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy. Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
8 Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients Completed NCT01542801 Phase 4 Norfloxacin;ciprofloxacin
9 Intestinal Decontamination With Rifaximin. Effects on the Inflammatory and Circulatory State in Patients With Cirrhosis and Ascites - A Randomised Controlled Clinical Study Completed NCT01769040 Phase 4 Rifaximin;placebo
10 The Use of Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis: a Multicenter, Open-label Randomized Clinical Trial Completed NCT01288794 Phase 4 Diuretics plus human albumin;Diuretics (standard medical treatment)
11 Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903): A Multicenter, Single-blind, Randomised Controlled Trial Recruiting NCT04028323 Phase 4 Terlipressin;Octreotide
12 Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment: a Double-blind Randomized Placebo-controlled Trial Recruiting NCT03024684 Phase 4 Atorvastatin;Placebo Oral Tablet
13 Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis- Child C: A Randomized Double Blind Control Trial Recruiting NCT03633279 Phase 4 Branched chain amino acid;Placebo
14 Angiotensin 2 as a Novel Treatment for Hepatorenal Syndrome Not yet recruiting NCT04048707 Phase 4 Angiotensin II;Midodrine;Octreotide;Albumin solution
16 Terlipressin as Treatment of Patients With Cirrhosis and Hepatorenal Syndrome. Effect on Survival and Renal Function. Multicenter, Randomized and Prospective Study Suspended NCT00287664 Phase 4 terlipressin
17 Albumin Administration in the Prevention of Hepatorenal Syndrome and Death in Patients With Cirrhosis, Bacterial Infections Other Than Spontaneous Bacterial Peritonitis and High Risk of Hospital Mortality Terminated NCT02034279 Phase 4 Albumin
18 Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis Terminated NCT00570960 Phase 4 Dextran 70
19 Terlipressin Given As I.V. Boluses Vs Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome (Hrs): Preliminary Results Of A Randomized Controlled Clinical Study. Unknown status NCT00742690 Phase 2, Phase 3 terlipressin given by intravenous boluses and albumin;terlipressin given by continuous intravenous infusion and albumin
20 Pros & Cons of Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1 in Intensive Care Unit. Unknown status NCT03455322 Phase 2, Phase 3 norepinephrine versus midodrine & octreotide
21 Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins? Unknown status NCT02443285 Phase 3 Cefotaxime;ceftriaxone
22 Principal Investigator Unknown status NCT01455337 Phase 3 pentoxifylline;Prednisolone
23 Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation Unknown status NCT03206658 Phase 3 Spironolactone 25 mg;Placebo oral capsule
24 A 3-Armed Prospective Randomized Controlled, Open-Labeled Phase II Trial to Evaluate Late Introduction of Cyclosporine or Everolimus Versus a 5-day Delay of Cyclosporine in Combination With MMF in Liver Transplant Recipients With MELD-Scores≥25 Unknown status NCT01023542 Phase 2, Phase 3 delayed, low-dose CNI;BU-CNI;BU-Everolimus
25 A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With Hepatorenal Syndrome Type 1 Completed NCT00089570 Phase 3 terlipressin;Placebo
26 A Multi-Center, Randomized, Placebo Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects With Hepatorenal Syndrome Type 1 (The CONFIRM Study) Completed NCT02770716 Phase 3 Terlipressin
27 The Use of Midodrine, Octreotide and Albumin in Refractory Ascites Completed NCT00240045 Phase 2, Phase 3 Midodrine, albumin, octreotide LAR;midodrine, octreotide, albumin
28 Phase 3, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin® (Terlipressin) (REVERSE Trial) Completed NCT01143246 Phase 3 Terlipressin;Placebo
29 Noradrenalin vs Terlipressin in Patients With Hepatorenal Syndrome.A Prospective, Randomized Study Completed NCT00370253 Phase 3 Terlipressin;Noradrenalin
31 Efficacy and Safety of Viusid, a Nutritional Supplement, in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. A Randomized, Controlled and Double Blind Study. Completed NCT00502086 Phase 3
32 Double-blind Randomized Controlled Trial of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis Completed NCT01809132 Phase 2, Phase 3 Anakinra;Pentoxifylline;Zinc Sulfate;Methylprednisolone
33 Single Centre, Prospective, Open, Non Controlled, Pilot Study for Efficacy and Security Evaluation of Low Nephrotoxicity Immunosuppression, Based on the Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction Completed NCT01453218 Phase 3 ATeGe-Fresenius
34 Simvastatin Effect in Portal Hypertension Measured by Portal Hemodynamic Gradient and Azygos Vein Doppler in Echoendoscopy Completed NCT02134626 Phase 3 Simvastatin;Placebo pill
35 Efficacy of Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin. A Multi-center Randomized Controlled Study Completed NCT00986817 Phase 3 Terlipressin;Placebo
36 Effect of Metoprolol Succinate in Cardiac Remodeling Related to Nonalcoholic Cirrhosis. Randomized Study. Completed NCT01676285 Phase 3 Metoprolol succinate;placebo
37 Randomized Trial, Masked, and Placebo Controlled to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension Completed NCT01456286 Phase 2, Phase 3 sapropterin
38 Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites Completed NCT02173288 Phase 2, Phase 3 Standard medical therapy;Tolvaptan;Midodrine
39 Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study Completed NCT02451033 Phase 2, Phase 3 standard medical therapy;G-CSF;Growth Hormone
40 The Effects of Anti-Viral Therapy on the Clinical Status, Quality of Life, and Survival of Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection Completed NCT02597166 Phase 3 Ledipasvir/Sofosbuvir
41 A Pilot Study to Determine the Safety and Efficacy of Induction-Therapy, De Novo MPA and Delayed mTOR-Inhibition in Liver Transplant Recipients With Impaired Renal Function. (PATRON-Study) Completed NCT00604357 Phase 3 anti-CD 25 mAb, Sirolimus, MMF
42 Comparison of The Effectiveness of Terlipressin Infusion Alone Vs Terlipressin With Noradrenaline Infusion In The Treatment of Hepatorenal Syndrome Type 1 Recruiting NCT03822091 Phase 3 Terlipressin;Terlipressin and Noradrenaline
43 Rifaximin Versus Norfloxacin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis Recruiting NCT04159870 Phase 3 Rifaximin;Norfloxacin
44 Granulocyte Colony Stimulating Factor Therapy In Decompensated Cirrhosis Of Liver: A Double Blinded Single Centre Randomised Controlled Trial Recruiting NCT03911037 Phase 2, Phase 3 G-CSF;Placebo
45 Evaluation of the Efficacy of an Antibiotic Combined With Standard Treatment in Severe Alcoholic Hepatitis Active, not recruiting NCT02281929 Phase 3 Amoxicillin;Placebo;Prednisolone
46 Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome (HRS): An Open Multicentric Randomized Study Terminated NCT00742339 Phase 2, Phase 3 Terlipressin plus albumin;Midodrine plus octreotide plus human albumin
47 Randomized, Double-Blind, Placebo-Controlled Trial Assessing Norfloxacin in the Prevention of Complications in Patients With Cirrhosis and Severe Liver Failure Terminated NCT01037959 Phase 3 Norfloxacin;Placebo
48 Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Stress Doses of Hydrocortisone on Renal Function and on Liver and Systemic Haemodynamics Unknown status NCT00657306 Phase 2 hydrocortisone;dextrose solution 5%
49 Effect of Intravenous Albumin (Standard vs Dose Reduced Regimen) On Renal Impairment and Mortality in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis: A Double Blind Randomized Clinical Trial Unknown status NCT00852800 Phase 2 Albumin;Albumin
50 An Exploratory Study of FE999908 in Patients With Hepatorenal Syndrome Type 1 Completed NCT01373606 Phase 1, Phase 2 Terlipressin

Search NIH Clinical Center for Hepatorenal Syndrome

Cochrane evidence based reviews: hepatorenal syndrome

Genetic Tests for Hepatorenal Syndrome

Anatomical Context for Hepatorenal Syndrome

MalaCards organs/tissues related to Hepatorenal Syndrome:

Liver, Kidney, Bone, Neutrophil, Heart, Skin, Testes

Publications for Hepatorenal Syndrome

Articles related to Hepatorenal Syndrome:

(show top 50) (show all 2344)
# Title Authors PMID Year
Renal failure in patients with cirrhosis: hepatorenal syndrome and renal support strategies. 54 61
20124895 2010
Balancing volume resuscitation and ascites management in cirrhosis. 61 54
20124894 2010
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. 54 61
19877168 2010
Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. 61 54
19238094 2009
Poor outcomes with treatment of hepatorenal syndrome type 1 with splanchnic vasoconstrictors and albumin: report of seven cases and review of the literature. 61 54
19918689 2009
Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. 61 54
19413694 2009
The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. 61 54
18492024 2009
Management of hepatorenal syndrome. 61 54
18539334 2008
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. 61 54
18471512 2008
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. 54 61
17939047 2008
Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. 61 54
17886336 2008
Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial. 61 54
18197961 2008
Ascites in cirrhosis: a review of management and complications. 61 54
17890787 2007
Possible increased risk of pulmonary edema in patients with hepatorenal syndrome on adding octreotide to albumin / noradrenaline therapies. 54 61
17496406 2007
[Hepatorenal syndrome: pathogenesis and treatment]. 54 61
17760404 2007
Role of endothelin and endothelin receptor antagonists in renal disease. 61 54
16919017 2006
The management of severe alcoholic liver disease and variceal bleeding in the intensive care unit. 61 54
16543796 2006
Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. 54 61
16393283 2006
Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. 54 61
16393223 2005
Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. 61 54
16123966 2005
A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. 61 54
16108036 2005
Preoperative optimization of patients with liver disease. 61 54
16534358 2005
Hepatorenal syndrome: a dreaded complication of end-stage liver disease. 61 54
15667508 2005
The use of albumin in patients with decompensated cirrhosis: the case in favor. 54 61
15729966 2005
[Role of albumin in the treatment of hepatorenal syndrome in cirrhosis]. 61 54
15710088 2005
[Advances in therapy for ascites and hepatorenal syndrome]. 61 54
15650969 2005
Reconsidering hepatorenal syndrome. Throw in the towel? Not so fast! 61 54
15620124 2004
Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. 61 54
15239086 2004
Terlipressin and albumin combination treatment in hepatorenal syndrome. 54 61
15244209 2003
Is the use of albumin of value in the treatment of ascites in cirrhosis? The case in favour. 54 61
14563190 2003
Terlipressin plus hydroxyethyl starch infusion: an effective treatment for hepatorenal syndrome. 61 54
12867805 2003
Terlipressin and albumin for the hepatorenal syndrome. 54 61
12668990 2003
Hepatorenal syndrome. 61 54
15094702 2003
Albumin versus crystalloid therapy in the management of hepatorenal syndrome: a model for using meta analysis in cost effectiveness studies and the design of clinical trials. 61 54
14728474 2003
Review article: albumin for circulatory support in patients with cirrhosis. 61 54
12423450 2002
Characterization of treatment dose delivered by albumin dialysis in the treatment of acute renal failure associated with severe hepatic dysfunction. 54 61
12425489 2002
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. 54 61
12297842 2002
Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. 54 61
12143045 2002
[The use of albumin infusion in decompensated liver cirrhosis]. 61 54
11899505 2002
Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. 61 54
11778928 2001
[Clinical study on hepatitis D virus-positive patients died from severe hepatitis B]. 61 54
11509140 2001
Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. 54 61
10905585 2000
Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. 61 54
10827226 2000
Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. 61 54
10728802 2000
Acute renal failure associated with liver disease in India: etiology and outcome. 61 54
11041294 2000
Plasma levels of endothelin-1 in patients with the hepatorenal syndrome after successful liver transplantation. 61 54
11052272 2000
Pathogenetic factors and clinical elements in ascites and hepatorenal syndrome during liver cirrhosis. 61 54
10638019 1999
Serum endothelin and atrial natriuretic peptide in cirrhotic patients with ascites and hepatorenal syndrome. 61 54
9830237 1998
Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. 54 61
9425914 1998
Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. 54 61
9007721 1996

Variations for Hepatorenal Syndrome

Expression for Hepatorenal Syndrome

Search GEO for disease gene expression data for Hepatorenal Syndrome.

Pathways for Hepatorenal Syndrome

Pathways related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
2 10.98 F2 ALB AFP

GO Terms for Hepatorenal Syndrome

Cellular components related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 REN NPPA LCN2 IL18 F2 EDN3
2 cell GO:0005623 9.7 LCN2 F2 EDN3 EDN1 AVPR1A AVP
3 endoplasmic reticulum lumen GO:0005788 9.56 F2 CST3 ALB AFP
4 extracellular space GO:0005615 9.44 REN NPPA LCN2 IL18 GPT F2

Biological processes related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.95 IL18 EDN3 EDN1 AVP
2 response to drug GO:0042493 9.95 REN LCN2 EDN1 CST3 AQP1
3 positive regulation of cell proliferation GO:0008284 9.91 F2 EDN3 EDN1 CST3 AVPR1A AVP
4 positive regulation of cell growth GO:0030307 9.83 F2 AVPR1A AVP
5 cellular response to hydrogen peroxide GO:0070301 9.8 LCN2 CST3 AQP1
6 cellular protein metabolic process GO:0044267 9.77 NPPA F2 CST3 ALB AFP
7 renal water homeostasis GO:0003091 9.71 AVP AQP2 AQP1
8 response to muscle stretch GO:0035994 9.68 NPPA EDN1
9 amyloid-beta metabolic process GO:0050435 9.67 REN ACE
10 positive regulation of renal sodium excretion GO:0035815 9.67 EDN1 AVPR1A
11 grooming behavior GO:0007625 9.67 AVPR1A AVP
12 maternal behavior GO:0042711 9.66 AVPR1A AVP
13 inositol phosphate-mediated signaling GO:0048016 9.66 EDN3 EDN1
14 angiotensin maturation GO:0002003 9.65 REN ACE
15 positive regulation of hormone secretion GO:0046887 9.64 EDN3 EDN1
16 artery smooth muscle contraction GO:0014824 9.64 EDN3 EDN1
17 multicellular organismal water homeostasis GO:0050891 9.63 AVP AQP1
18 positive regulation of glutamate secretion GO:0014049 9.63 AVPR1A AVP
19 glycerol transport GO:0015793 9.62 AQP2 AQP1
20 positive regulation of prostaglandin biosynthetic process GO:0031394 9.61 AVPR1A AVP
21 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.61 EDN3 EDN1
22 negative regulation of transmission of nerve impulse GO:0051970 9.6 AVPR1A AVP
23 peptide hormone secretion GO:0030072 9.59 EDN3 EDN1
24 positive regulation of cellular pH reduction GO:0032849 9.58 AVPR1A AVP
25 vein smooth muscle contraction GO:0014826 9.58 EDN3 EDN1
26 regulation of vasoconstriction GO:0019229 9.58 EDN3 EDN1 ACE
27 negative regulation of female receptivity GO:0007621 9.57 AVPR1A AVP
28 maternal aggressive behavior GO:0002125 9.56 AVPR1A AVP
29 cellular response to mercury ion GO:0071288 9.52 AQP2 AQP1
30 penile erection GO:0043084 9.51 AVPR1A AVP
31 vasoconstriction GO:0042310 9.5 EDN3 EDN1 AVP
32 cellular response to water deprivation GO:0042631 9.49 AVPR1A AQP2
33 nitric oxide transport GO:0030185 9.48 EDN1 AQP1
34 renal water transport GO:0003097 9.46 AQP2 AQP1
35 regulation of blood pressure GO:0008217 9.46 REN NPPA EDN1 ACE
36 water transport GO:0006833 9.43 AVP AQP2 AQP1
37 positive regulation of systemic arterial blood pressure GO:0003084 9.13 AVPR1A AVP ACE
38 positive regulation of heart rate GO:0010460 8.92 NPPA EDN3 EDN1 AVPR1A

Molecular functions related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.56 NPPA EDN3 EDN1 AVP
2 water channel activity GO:0015250 9.43 AQP2 AQP1
3 water transmembrane transporter activity GO:0005372 9.4 AQP2 AQP1
4 endothelin B receptor binding GO:0031708 9.37 EDN3 EDN1
5 glycerol transmembrane transporter activity GO:0015168 9.32 AQP2 AQP1
6 enterobactin binding GO:1903981 9.16 LCN2 ALB
7 signaling receptor binding GO:0005102 9.1 REN NPPA F2 EDN3 EDN1 AVP
8 V1A vasopressin receptor binding GO:0031894 8.96 AVPR1A AVP

Sources for Hepatorenal Syndrome

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....